Literature DB >> 6970577

Survivorship in systemic lupus erythematosus: effect of antibody to extractable nuclear antigen.

M C Hochberg, C A Dorsch, E J Feinglass, M B Stevens.   

Abstract

The course of 81 patients with systemic lupus erythematosus (SLE) who had sera tested for antibody to extractable nuclear antigen (ENA) was studied to determine the effect of the presence of antiENA antibody on survivorship. There were no differences in percent survival between the patients with and without antibody to ENA or those with and without antibody to the ribonucleoprotein (RNP) component of ENA. We conclude that there is no prognostic advantage to the presence of either antiENA or antiRNP antibody in patients with SLE.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6970577     DOI： 10.1002/art.1780240109

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


  7 in total

1.  Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil.

Authors:  Eutília A M Freire; Inês O Maia; Jamile C A Nepomuceno; Rozana M Ciconelli
Journal:  Clin Rheumatol       Date:  2007-01-10       Impact factor: 2.980

Review 2.  Systemic lupus erythematosus clinical issues.

Authors:  M B Stevens
Journal:  Springer Semin Immunopathol       Date:  1986

3.  Systemic lupus erythematosus: follow-up study of 148 patients. I: Classification, clinical and laboratory findings, course and outcome.

Authors:  P Halberg; B Alsbjørn; J T Balsløv; J Gerstoft; I Lorenzen; S Ullman; A Wiik
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

4.  Antinuclear antibodies in routine analysis: the relevance of putative clinical associations.

Authors:  A J Swaak; V Huysen; R J Smeenk
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

5.  Relationship of precipitating antibodies to soluble cellular antigens and histologically defined renal lesions in systemic lupus erythematosus.

Authors:  P J Venables; T Yi; D F Woodrow; J Moss; R N Maini
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

6.  Is MCTD a distinct entity? Comparison of clinical and laboratory findings in MCTD, SLE, PSS, and RA patients.

Authors:  L S De Clerck; K A Meijers; A Cats
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

7.  Follow-up of 151 patients with high-titer U1RNP antibodies.

Authors:  P B Frandsen; N J Kriegbaum; S Ullman; M Høier-Madsen; A Wiik; P Halberg
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.